A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old

Conditions

• Enterovirus Infections

Interventions

• BIOLOGICAL: EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)
• BIOLOGICAL: EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)
• BIOLOGICAL: EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)
• BIOLOGICAL: EV71 vaccine (2 μg total protein per dose)
• BIOLOGICAL: EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)
• BIOLOGICAL: EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)
• BIOLOGICAL: EV71 vaccine (1 μg total protein per dose)

Sponsor

Enimmune Corporation